Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Article
[키워드] administration
antibody
approved
Booster vaccine
Combination
Community
consequence
current
Delta
delta variant
diagnosed
dominant
dominant variant
Efficacy
Evolution
FDA
higher infectivity
human lung tissue
immune
Immune escape
immune evasion
Immunity
immunocompromised individual
IMPROVE
Infection
less
monoclonal
monoclonal antibodies
Mutation
mutations
neutralising
omicron
Omicron variant
other variant
Protein
public health
recombination event
reduced
reduction
reported
SARS-CoV-2
SARS-CoV-2 variant
SARS-CoV-2 variants
several variants
severity
Sotrovimab
spike
Spread
syncytia formation
the SARS-CoV-2
therapeutic use
Transmission
Vaccine
variant
variants of SARS-CoV-2
Wuhan-Hu-1
zoonotic
[DOI] 10.1002/rmv.2381 PMC 바로가기
[DOI] 10.1002/rmv.2381 PMC 바로가기